HK Stock Market Move | PEIJIA-B (09996) rose more than 6% and the registration application for the Taurus NXT system has been accepted. The chairman will begin increasing holdings this month.

PEIJIA-B(09996) rose more than 6%, as of press time, rose 6.32% to 5.89 Hong Kong dollars, with a turnover of 1.9895 million Hong Kong dollars. On the news front, on the evening of December 7th, Peijia Medical announced that recently, the company received a notice of acceptance from the National Medical Products Administration of the People's Republic of China, confirming the acceptance of the registration application of the TaurusNXT "non-aldehyde cross-linked" aortic valve replacement system by transcatheter aortic valve replacement ("TAVR"). TaurusNXT is the company's internally developed third-generation TAVR system, which uses patented non-aldehyde biological tissue cross-linking technology aimed at improving the durability and biocompatibility of prosthetic aortic valves. In addition, Peijia Medical disclosed that the Board of Directors has learned that Dr. Zhang Yi, Executive Director, Chief Executive Officer, and Chairman of the Board of Directors of the Company, has begun purchasing company shares through a company controlled by him on the open market starting from December 1, 2025, at a total expected cost not exceeding 15 million Hong Kong dollars. According to Dr. Zhang, the increase in shareholding reflects his recognition of the company's intrinsic value, as well as his strong confidence in the company's future prospects and growth potential.